CN103127502A - 使用il-21和单克隆抗体疗法治疗癌症的方法 - Google Patents

使用il-21和单克隆抗体疗法治疗癌症的方法 Download PDF

Info

Publication number
CN103127502A
CN103127502A CN2013100575165A CN201310057516A CN103127502A CN 103127502 A CN103127502 A CN 103127502A CN 2013100575165 A CN2013100575165 A CN 2013100575165A CN 201310057516 A CN201310057516 A CN 201310057516A CN 103127502 A CN103127502 A CN 103127502A
Authority
CN
China
Prior art keywords
cell
polypeptide
rituximab
fragment
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013100575165A
Other languages
English (en)
Chinese (zh)
Inventor
W·R·金德斯沃格尔
S·D·胡格赫斯
R·D·豪雷
C·H·克雷格
D·C·弗斯特
R·A·约翰逊
M·D·黑佩尔
P·V·斯瓦库玛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of CN103127502A publication Critical patent/CN103127502A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2013100575165A 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法 Pending CN103127502A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US57297304P 2004-05-20 2004-05-20
US60/572,973 2004-05-20
US63538004P 2004-12-10 2004-12-10
US60/635,380 2004-12-10
US67128105P 2005-04-14 2005-04-14
US60/671,281 2005-04-14
US68044705P 2005-05-12 2005-05-12
US60/680,447 2005-05-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN 200580021262 Division CN101084012A (zh) 2004-05-20 2005-05-20 使用il－21和单克隆抗体疗法治疗癌症的方法

Publications (1)

Publication Number Publication Date
CN103127502A true CN103127502A (zh) 2013-06-05

Family

ID=34971701

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011101079712A Expired - Fee Related CN102188704B (zh) 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法
CN2013100575165A Pending CN103127502A (zh) 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2011101079712A Expired - Fee Related CN102188704B (zh) 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法

Country Status (15)

Country Link
US (8) US20050265966A1 (enExample)
EP (4) EP2428216A3 (enExample)
JP (2) JP4982373B2 (enExample)
KR (1) KR101236177B1 (enExample)
CN (2) CN102188704B (enExample)
AU (1) AU2005245031B2 (enExample)
BR (1) BRPI0511187A (enExample)
CA (1) CA2566745A1 (enExample)
CY (1) CY1113287T1 (enExample)
DK (1) DK1758610T3 (enExample)
ES (1) ES2390278T3 (enExample)
IL (1) IL179099A (enExample)
PL (1) PL1758610T3 (enExample)
PT (1) PT1758610E (enExample)
WO (1) WO2005113001A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
EP2428216A3 (en) * 2004-05-20 2012-05-23 ZymoGenetics, Inc. Methods of treating cancer using IL-21 and monoclonal antibody therapy
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
US8506933B2 (en) * 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
CA2770680A1 (en) * 2009-08-10 2011-02-17 Msdx, Inc. Methods of detecting responses to therapies using perforin levels
WO2011066460A1 (en) * 2009-11-27 2011-06-03 Msdx, Inc. Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition
US8673309B2 (en) 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
WO2013109904A1 (en) * 2012-01-19 2013-07-25 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
WO2013169693A1 (en) * 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
SG10201913627TA (en) 2014-04-08 2020-03-30 Boston Pharmaceuticals Inc Binding molecules specific for il-21 and uses thereof
KR20160120157A (ko) * 2015-04-07 2016-10-17 주식회사 메드팩토 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
WO2018067602A1 (en) * 2016-10-03 2018-04-12 Baylor College Of Medicine Modulating cytotoxic cell lytic granule positioning to promote diffuse killing in cellular therapies
CN111316098B (zh) * 2017-09-15 2024-05-14 拜克门寇尔特公司 用于治疗的基于流动的测定
KR102265437B1 (ko) 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2003103589A2 (en) * 2002-06-07 2003-12-18 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092468T3 (es) 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
KR101063278B1 (ko) * 1998-08-11 2011-09-07 바이오겐 아이덱 인크. Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
WO2001001748A2 (en) * 1999-07-02 2001-01-11 Genentech, Inc. Peptide compounds that bind her2
IT1311703B1 (it) 1999-07-23 2002-03-19 Sipa Spa Impianto ad alta efficienza di soffiaggio di preforme
DE60125543T2 (de) 2000-04-05 2007-10-04 Zymogenetics, Inc., Seattle Löslicher zytokinrezeptor zalpha11
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
WO2003049694A2 (en) 2001-12-07 2003-06-19 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
EP2295468B1 (en) * 2002-02-14 2015-07-08 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
BR0309254A (pt) * 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
JP4790413B2 (ja) * 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド 抗体療法
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
AU2003302250B2 (en) * 2002-12-13 2009-08-27 Zymogenetics, Inc. IL-21 production in prokaryotic hosts
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
EP1680138B1 (en) * 2003-10-17 2013-07-17 Novo Nordisk A/S Combination therapy
EP2428216A3 (en) * 2004-05-20 2012-05-23 ZymoGenetics, Inc. Methods of treating cancer using IL-21 and monoclonal antibody therapy
JP2008521406A (ja) * 2004-11-24 2008-06-26 フレッド ハッチンソン キャンサー リサーチ センター 養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2003103589A2 (en) * 2002-06-07 2003-12-18 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADRIANNA MOROZ: "IL-21 Enhances and Sustains CD8~+T Cell Responses to Achieve Durable Tumor Immunity:Comparative Evaluation of IL-2,IL-15,and IL-21", 《THE JOURNAL OF IMMUNOLOGY》 *
肖溶: "Ⅰ类细胞因子超家族新成员--IL-21", 《生命的化学》 *

Also Published As

Publication number Publication date
CN102188704B (zh) 2013-04-24
US20090087404A1 (en) 2009-04-02
PL1758610T3 (pl) 2012-11-30
US20110300098A1 (en) 2011-12-08
JP4982373B2 (ja) 2012-07-25
PT1758610E (pt) 2012-10-01
CA2566745A1 (en) 2005-12-01
BRPI0511187A (pt) 2007-12-04
IL179099A (en) 2011-03-31
JP2012102122A (ja) 2012-05-31
EP2431050A1 (en) 2012-03-21
EP1758610B1 (en) 2012-07-04
HK1160776A1 (en) 2012-08-17
KR20070026588A (ko) 2007-03-08
US20070048264A1 (en) 2007-03-01
US20110086004A1 (en) 2011-04-14
KR101236177B1 (ko) 2013-02-22
EP2428216A9 (en) 2012-04-25
EP2425847A1 (en) 2012-03-07
US20070122382A1 (en) 2007-05-31
DK1758610T3 (da) 2012-10-15
EP2431050A8 (en) 2012-09-26
CY1113287T1 (el) 2016-04-13
US20050265966A1 (en) 2005-12-01
EP2428216A3 (en) 2012-05-23
AU2005245031B2 (en) 2011-08-18
AU2005245031A1 (en) 2005-12-01
US20090269304A1 (en) 2009-10-29
US20070178063A1 (en) 2007-08-02
WO2005113001A1 (en) 2005-12-01
EP2428216A2 (en) 2012-03-14
CN102188704A (zh) 2011-09-21
ES2390278T3 (es) 2012-11-08
IL179099A0 (en) 2007-03-08
JP2007538108A (ja) 2007-12-27
EP1758610A1 (en) 2007-03-07

Similar Documents

Publication Publication Date Title
Pillarisetti et al. A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma
CN102188704B (zh) 使用il-21和单克隆抗体疗法治疗癌症的方法
Kohrt et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Josephs et al. Tumour-associated macrophage polarisation and re-education with immunotherapy
Yano et al. Defucosylated anti–CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory mycosis fungoides and Sézary syndrome
CN118317789A (zh) 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用
CN101084012A (zh) 使用il－21和单克隆抗体疗法治疗癌症的方法
HK1160776B (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
Yoo et al. LIGHT (TNFSF14) costimulation with TIGIT blockade broadens the activity of checkpoint inhibitors (CPIs) into CPI refractory and resistant tumors through targeted myeloid cell and effector lymphocyte activation
HK1167338A (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
Στραβοκεφάλου The role of cellular immunity in the treatment of cancer
HK1167803A (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
Visser Exploring novel therapeutic approaches for the treatment of hematological malignancies: a focus on autophagy and immunotherapy
HK1167337A (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
CN118924893A (zh) Bcmap329g抗体及car-t细胞在治疗多发性骨髓瘤中的应用
Cai et al. A computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action
Solomon Targeting regulatory T cells for therapeutic gain in cancer therapy
Franz Demane Defining and targeting combination immunotherapies in mouse models of cancer
Guyre et al. FcγR-directed immunotherapies
Burlion et al. A novel combination of cyclophosphamide and anti-ICOS mAb prevents tumor growth by affecting regulatory T cells in mice with a human immune system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130605